Evidence map›Paper›PMID 26526051›Full record

ArticlePeritoneal dialysis international : journal of the International Society for Peritoneal Dialysis

Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions.

Robiyanto Robiyanto, Syed Tabish R Zaidi, Madhur D Shastri, Ronald L Castelino, S Troy Wanandy, Matthew D Jose, Rahul P Patel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis · 2016
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Robiyanto RobiyantoPharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
Syed Tabish R ZaidiPharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
Madhur D ShastriPharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
Ronald L CastelinoPharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia.
S Troy WanandyPharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia Medicine, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia Department of Pharmacy, Royal Hobart Hospital, Hobart, Tasmania, Australia.
Matthew D JoseMedicine, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia Department of Nephrology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
Rahul P PatelPharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia Rahul.Patel@utas.edu.au.
University of Tasmania · AURoyal Hobart Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelled♦

introductionIntraperitoneal tigecycline is a potential option for the treatment of peritoneal dialysis (PD)-associated peritonitis caused by microorganisms resistant to commonly used antibiotics. However, the stability of tigecycline must be assessed in the PD solution before evaluating its safety and therapeutic efficacy in PD-associated peritonitis. The objective of this study was to investigate the stability of tigecycline in 3 types of PD solutions at different temperatures for various time points. ♦

methodsA total of 27 PD bags (9 PD bags for each type of PD solution; 1.5% glucose, 7.5% icodextrin, and 1.5% glucose pH neutral) containing 2 μg/mL of tigecycline were prepared and stored at either 4, 25, or 37°C. An aliquot was withdrawn immediately before (0 hour) and after pre-defined time points. Each sample was analyzed in duplicate for the concentration of tigecycline using a stability-indicating high-performance liquid chromatography (HPLC) technique. Samples were also assessed for pH, color changes, and evidence of precipitation immediately after preparation and on each day of analysis. ♦

resultsTigecycline in all 3 types of PD solutions retained more than 90% of its initial concentration for at least 216, 72, and 8 hours at 4, 25, and 37°C, respectively. There was no evidence of precipitation at any time under the tested storage conditions. The pH and color of tigecycline admixed PD solutions stored at 4, 25, and 37°C remained essentially unchanged for 336, 96, and 48 hours respectively. ♦

conclusionThe results obtained from the study provide a platform for future clinical studies aiming to determine the safety and therapeutic efficacy of intraperitoneally administered tigecycline for the treatment of PD-associated peritonitis.

Indexed as

Anti-Bacterial AgentsDialysis SolutionsDrug StabilityPeritoneal DialysisChromatography, High Pressure LiquidHumansMinocyclinePeritonitisTemperatureTigecyclineTime FactorsAnti-Bacterial AgentsDialysis SolutionsMinocyclineTigecyclineglucosehigh-performance liquid chromatographyicodextrinperitoneal dialysispH neutralstabilityTigecycline

Identifiers

PMID26526051
PMCPMC4934435
OpenAlexW2262978135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.